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ABBREVIATIONS
APTT - Activated partial thromboplastin time
PT - Prothrombin time
INR - International Normalised ratio
FDP - Fibrinogen Degradation Product
AP - Acute pancreatitis
APACHE - The Acute Physiology and Chronic Health evaluation
CRP - C- reactive protein
CT - Computerised Tomography
USG - Ultra sonogram
ASA - Aminosalyclic acid
ERCP - Endoscopic retrograde Cholongio pancreatography
BISAP - Blood urea nitrogen/Impaired mentalstatus/SIRS
score/Age/pleural effusion.
IL - Interleukins
CTSI - Computerised tomography severity index.
TF - Tissue factor
Vwf - Vonwillibrand factor.
SIRS - Systemic inflammatory response syndrome
DIC - Disseminated Intrvascular coagulation
PAI - Platelet activator inhibitor.
ISTH - International society on thrombosis and haemostasis.
APC - Activated Protein C
MMP - Matrix metalloproteinase
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INTRODUCTION
Acute pancreatitis was defined in the Atlanta symposium as an acute
inflammatory process involving the pancreas that further involve
peripancreatic tissues and organs remote from the pancreas. Criteria had been
defined for severity which include organ failure (Pulmonary
insufficiency,shock and renal failure) and /or complications involving locally
which include pseudocyst.pancreatic necrosis and pancreatic abscess41 .
The diagnosis of the disease requires 2 out of the following 3 features43:
1) Abdominal pain characteristic of acute pancreatitis.2) serum amylase and
/or lipase which is  3 times the upper limit of normal and 3) characteristics
findings in Imaging ( USG/CT scan).The severity of acute pancreatitis does
not correlate with the rise in level of serum lipase and amylase.Risk factors of
severity of acute pancreatitis at admission include older age,obesity and organ
failure.
Tests at admission which distinguish mild from severe acute pancreatitis
include APACHE-11 score(8-suggestive of severe AP) and serum
haematocrit ( <44 suggests mild acute pancreatitis). A high CRP level
measured within 72hours correlates with formation of pancreatic necrosis.
Pancreatic necrosis and persistent organ failure were the most important
factors responsible for severity in acute pancreatitis29.The most important
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investigation to distinguish interstitial from necrotizing type of acute
pancreatitis is CECT abdomen and it is more sensitive and specific especially
if taken 2-3 days after the onset of illness. Mortality rate increases to >40%
when the multisystem organ failure coexistent with necrotizing type of acute
pancreatitis.
The commonest etiological factors observed in AP were Chronic
Alcohol abuse and Gallbladder stones11. They comprise about 80% of all
cases (Forsmark et al 2007). Around 10% of the cases, the cause was
unknown (Tonsi et al 2009). Some other causes of Acute pancreatitis were
hypercalcemia, hypertriglyceridemia, trauma, drugs like methyldopa, 5-
ASA, L-asparginase, scorpion sting, duodenal diverticula,parasites,annular
pancreas, choledochocele, infections (coxackie,measles, mycoplasma,
leigonella, leptospira, salmonella and tuberculosis) , hereditary ,
autoimmune causes ,tumors ,endoscopic retrograde cholangiopancreatography
(ERCP) and developmental abnormalities.
The Theory behind the pathogenesis of acute Pancreatitis was proposed
as acinar cells injury, which in turn leads into pancreatic enzymes leakage
into pancreatic tissue. These enzymes get activated and initiate the process of
auto digestion 19. The proteases which were activated ie., elastase,trypsin and
3
lipase breaks down cell membranes and tissues which in turn causes
vascular damage, oedema,, haemorrhage and necrosis.
The development of acute necrotizing pancreatitis is usually associated
with pancreatic glandular necrosis. Acinar cell apoptosis, the release of
cytokines, activation of coagulation, tissue ischemia, and tissue necrosis are
key factors in the progression of the condition38, as well as in the
development of associated extrapancreatic complications. (Steinberg &
Tenner, 1994; McKay & Buter, 2003; Pandol et al., 2007).
Atlanta classification divided acute pancreatitis into two broad
categories36,41
Mild Acute Pancreatitis :(edematous and interstitial)
It was defined as pancreatitis associated with minimal organ dysfunction
and an uneventful recovery.
Severe Acute pancreatitis :(necrotizing ) 42.
Criteria for severe acute pancreatitis included any of the following:
A Ranson’s score of 3 or more and /or an APACHE11 score of 8 or
more within the first 48hours , Organ failure ( respiratory,circulatory,renal and
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/or gastrointestinal bleeding ) and /or local complications( pancreatic necrosis,
abscess or pseudocyst).
Predictive marker for severity37 :
Clinical assessment,clinicophysiological scoring systems, imaging
techniques and biochemical markers.
There are Prognostic system criteria for assessing severity including
Atlanta severity criteria, Ranson’s criteria ,Glasgow score, APACHE11 score,
SIRS score, recent severity score like BISAP score, Panc 3 score, Japanese
severity score, Harmless acute Pancreatitis Score and artificial network scores.
Apart from these, Biochemical scores like C- reactive Protein, Procalcitonin,
Serum Amyloid A, Trypsinogen Activation Peptide, Polymorphonuclear
Granulocyte Elastase, Interleukins IL-6&MCP-1,Hematocrit and BUN 28.
In spite of all these clinical & biological markers ,There is yet no single
marker could serve as an optimal predictor of disease severity in acute
pancreatitis48.
Hence imaging methods like ultra sonogram ,computed tomography,
Echo – enhanced ultrasound,Magnetic Resonance Imaging been tried to assess
the severity of acute pancreatitis.
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Of the imaging methods Contrast enhanced CT scan abdomen is
currently the best imaging method recognised for assessment of severity in
acute pancreatitis. Balthazar and his co-workers formulated a new index called
as CT severity index(CTSI) which showed a good correlation with the
clinical parameters in patients with acute pancreatitis.
CT grade as per Balthazar score 35
A - normal
B - focal or diffuse enlargement of the pancreas, including
irregularities of contour and inhomogeneous attenuation;
C - pancreatic gland abnormalities in B plus peripancreatic
inflammation;
D - grade C plus a single fluid collection;
E - grade C plus 2 or more fluid collections and /or the
presence of gas in or adjacent to pancreas.
This index scores the degree of pancreatic inflammation and necrosis on
a scale with a maximum of 10points.Patients with a severity index of 0-1
exhibited no morbidity or mortality, whereas 4% morbidity rate and no
mortality rate were seen with CT severity index of 2. In contrast, patients with
a CT severity index of 7-10 yielded 92% morbidity and 17% mortality rate39.
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Mortele et al modified the CTSI by introducing extrapancreatic
complications( Pleural effusion,ascites,vascular and GI complications)
Modified CT Severity Index34
Prognostic Indicator Points
Pancreatic inflammation
Normal pancreas 0
Intrinsic pancreatic abnormalities with/without
inflammatory changes in peripancreatic fat
2
Pancreatic or peripancreatic fluid collection or
peripancreatic fat necrosis
4
Pancreatic necrosis
None 0
<30% 2
>30% 4
Extrapancreatic complications
One or more of pleural
effusion,ascites,vascular
complications,parenchymal complications,or
gastrointestinal involvement.
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The Haematological and coagulation parameters were assessed in the
study population and these indices are correlated with the severity of disease
which was defined by the above CT Severity Index criteria.
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AIM OF THE STUDY
To Study the Haematological and coagulation changes prospectively in
patients with acute pancreatitis and correlating the changes to its severity.
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REVIEW OF LITERATURE
Haematological and coagulation abnormalities in acute pancreatitis
were noted in literature studies 1.
Trapnell (1966)in his study reported falls in values of hemoglobin,
white blood cell count and haematocrit in acute pancreatitis patients9.
Innerfield, Angrist and Benjamin (1952) noted a state of
hypocoagulability, whereas other workers have observed a
hypercoagulable state. (Shinowara et al., 1963)8.
Disseminated intravascular coagulation (DIC) has been observed in
acute pancreatitis4 (Minna, Robboy and Colman, 1974; Yoshikawa, Tanaka
and Guze, 1971) and post-mortem studies also have confirmed the presence of
widespread thrombosis in a proportion of cases.(Smyth, 1940).
Desmond Murphy and Clement W.Imrie in their study showed fall in
Hemoglobin (48%) and Haematocrit (88%) of their patients. They also showed
reticulocytosis in 22% of their patients.
The fall in hemoglobin and haematocrit may be caused by a
combination of hemodilution ,intravascular coagulation and blood loss into
and around the pancreas1, and also been noted previously(Trapnell,1966).
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Gastric erosions, acute peptic ulceration and bleeding into the pancreatic
tissues or a pseudo-cyst, are usually considered the major causes of a falling
hemoglobin in patients with acute pancreatitis, and this additional cause must
be kept in mind.
Leucocytosis has been observed in patients with AP and has been
related to the more severe form of the disease.
Normal Haemostasis:
Haemostasis normally involve endothelial cells and vessel wall and
soluble plasma proteins like coagulation proteins with their regulators,
cellular components in blood which included, platelets ,RBC and leukocytes21.
It also include microparticles derived from leukocytes and platelets.. This is
a physiologic process which has the capacity to produce a haemostatic plug
outside a damaged blood vessel and also controls the fluidity of blood.
Thrombosis was yet another event which takes place inside the lumen of
the vessel , consists of following events which include 22
a) accumulation of platelets,
b) activation,
c) adhesion of platelets
d) aggregation of platelets
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e) and fibrin formation preceded by TF-initiated thrombin generation.
Thrombin formation along with coagulation of blood occurring in
vascular damaging site, is induced by platelets which were adherent to vessel
wall. The haemostatic process was counter-balanced by anticoagulant
mechanisms in normal individual which ensure the regulation of haemostatic
effect. In pathological states (e.g. in systemic inflammation), the haemostatic
events escapes the control mechanism ,leading to thrombosis.
Coagulation Model :
Years before, the coagulation model was proposed which was called
“cascade model” and it was classified into intrinsic and extrinsic pathways,
and the common pathway was united at the factor X level. (Macfarlane
1964,Davie and Ratnoff 1964;) This model proposed that coagulation of
blood involves a series of calcium-dependent conversions of proenzymes to
the serine proteases .26.This event converts prothrombin into thrombin
(Dahlback 2000).
The extrinsic pathway which occurs after the vascular damage, where
in the tissue factor is exposed to the circulation which binds and transfers
factor VII to FVIIa. The TF-FVIIa forms a complex and this complex is
responsible for activating FIX to FIXa and FX to FXa33.
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The intrinsic pathway involves factor XII contact activation and it
occurs only in the presence of HMWK and prekallikrein . The FXIIa is
responsible for activation of factorXI to XIa. This event further activates
factor IX to IX a. Finaly FIXa activates both factor VIIIa and factor X.
The common pathway involves both FXa and Factor Va by forming a
prothrombinase complex, thereby causing conversion of prothrombin to
thrombin which in turn converts fibrinogen to fibrin30. The contribution of
platelets was considered to be an independent mechanism in primary
hemostasis. APTT measures the intrinsic pathway whereas PT measures the
extrinsic pathway and these 2 tests were important in hemostasis .
Platelets role in acute pancreatitis:
The platelet plug intermingled with the fibrin meshwork forms the
thrombus formation . Fibrinogen and Von Willi brand factor (VWF) initiates
the adhesion of platelets of vascular injury site. These factors are important
for the propagation and amplification phases of coagulation12. These factors
provide a surface of the damaged area which lies in close proximity.The
elements for coagulation were situated in that area.Vascular damage expose
the collagen which in turn activate the platelets and formation of thrombin.
Studies have shown that in acute pancreatitis, platelets were activated , and
hence their indices were altered along with some functional changes31.
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Evidence of increased platelet activation associated with pancreatitis has
long been established in experimental animal models. In rabbits,
administration of pancreatic fluid from patients with chronic pancreatitis
induced platelet aggregation and activation (Prinz et al., 1984). In cases of
acute pancreatitis, activated platelets along with indices ie., Platelet large cell
ratio, platelet mean volume and distribution width have also been shown to be
elevated between onset and remission of AP(Mimidis et al., 2004).
While a heightened platelet response is typical of patients with mild AP,
a decreased platelet count (due to increased consumption of platelets) is
observed in cases of severe AP49. Low plasma levels of platelets in patients
with AP are also associated with poor clinical outcome(Maeda et al., 2006).
DIC is a condition which is acquired by intravascular fibrin deposition
and microvascular thrombosis following a systemic activation of coagulation2.
Bleeding occurs due to increased consumption of coagulation factors and
platelets .The organ failure occurs due to vascular thrombosis32.
DIC is associated with conditions like malignancy, hepatic failure,
immunological/toxic reactions, vascular abnormalities and organ failure
conditions like severe acute pancreatitis. DIC is of two types6. The first type is
visible one which can be detected by clinical and laboratory method. The other
one is invisible which can not be detected by clinical and laboratory method51.
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The former one is more dangerous as it indicates a decompensated
hemostatic system2. Sepsis and Trauma were the commonest condition leading
to DIC in 30% and 50% respectively10, which further increases the death risk
in these patients.
Studies have shown that activation of pancreatic enzymes do have role
in pathogenesis of Disseminated intravascular coagulation.5
The effects of DIC were natural anticoagulant system suppression,
fibrinolytic system suppression due to increased level of PAI-1 and there was
increase in production of fibrin2,6 .Thus all anticoagulant mechanism were
suppressed during the course of DIC6.
ISTH Diagnostic Scoring System for DIC
Risk assessment: Does the patient with underlying disorder known to be
associated with overt DIC?
• If yes proceed further
• If not, don’t use this algorithm.
Order global coagulation tests (PT, platelet count, fibrinogen, D-dimer)
Score the test results:
• Platelet count (>100 k/µL = 0, <100 k/µL = 1, <50 k/µL = 2)
• Elevated D-dimer (<0.4 µg/mL = 0, 0.4–4.0 µg/mL = 2, >4.0 µg/mL=3)
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• Prolonged PT (<3 sec = 0, >3 sec but <6 sec = 1, >6 sec = 2)
• Fibrinogen level (>100 mg/dL = 0, <100 mg/dL = 1)
Calculate score:
• If 5, compatible with overt DIC: Repeat score daily.
• If <5, suggestive (not affirmative) for nonovert DIC: Repeat next 1–2
days.
Coagulative disturbances in acute pancreatitis :
Accelerated fibrinolysis and consumptive coagulopathy are the known
coagulation abnormalities that can occur in severe AP and they are related to
organ failure3,7.
Perfusion and hypoxia of pancreatic organ plays vital role in formation
of pancreatic necrosis46.There are several studies which states that micro
vascular abnormalities like inadequate perfusion,shunting,vasoconstriction and
increased blood viscosity are responsible for progression of AP7. Pancreatic
tissue blood flow is another factor when it gets reduced, is a marker of severe
AP47.
Blood coagulation parameters such as activated partial thromboplastin
time and prothrombin time measures the intrinsic and extrinsic coagulation
pathways respectively. Studies have shown that an elevated prothrombin time
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in patients with AP (Radenkovic et al., 2009). However, there have been no
reports of significant alterations in partial thromboplastin time (APTT) levels
in these patients. with AP 3. While these measurements suggest some early
haemostatic disturbances of AP, their usefulness in predicting patient outcome
is questionable. Clinical studies which measure other parameters (most
notably FDP and antithrombin) have demonstrated an improved specificity and
sensitivity in predicting outcome for these parameters than PT or APTT.
Sawa et al in his study have shown that Plasma TF23 had higher value
when compared with normal volunteers in severe AP, but the difference is not
statistically significant.
Plasma levels of TF in alcoholic severe AP27 with pancreatic necrosis
was significantly higher than that in alcoholic severe AP without pancreatic
necrosis or that in nonalcoholic severe AP with pancreatic necrosis. These
findings suggest that an increase in plasma TF may be related to the
development of pancreatic necrosis in alcoholic severe AP44.
Markedly elevated plasma fibrinogen levels,elevated FDP levels are
consistent with intravascular coagulation although they may be interpreted as
a non-specific reaction to injury40.These changes have been noted previously
in acute pancreatitis and these changes were attributed to a hypercoagulable
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state (Shinowara et al., 1963; Hirayama et al., 1974; Mungall and Hague,
1975).
The Other possible explanations for elevated FDPs in patients with
acute pancreatitis include obstructive jaundice, liver disease, pulmonary
embolus and venous thrombosis (Merskey et al., 1966) or local haemorrhage
(Malleson, 1974).
Therapeutic approach in modulating hemostasis in AP :
Recombinant Drotrecogin alpha activated was the first biological
agent studied in improving survival in patients with severe sepsis15. Activated
Protein C was used as a cytoprotective signaling molecule involved in
apoptosis, inflammation and vascular permeability17. This was first studied in
rat model and it was shown to result in significant decreases in serum IL-
8,TNF levels and MMP-9, an enzyme which degrades extracellular matrix
components in larger range18. Coagulopathy in severe AP was characterized
by significantly prolonged APTT and PT, marked leukocytosis, and
thrombocytopenia, decreased fibrinogen levels which were not significant in
Treated versus untreated APC rats. Alsfasser et al., 2006; Chen et al., 2007 and
Yamanel et al., 2005 have shown survival benefit in various models in AP
after the success of rat model.
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Chen et al., 2007 in his Study have demonstrated good efficacy when
treated with high bolus APC injections and also Alsfasser et al demonstrated
infusion in hourly basis in 200645.Some studies suggested that APC doesn’t
offer any survival benefit in early phase Acute pancreatitis14. When APC was
used in lower dose of 24 ug/kg, it offers no therapeutic benefit compared with
APC bolus ie., 100 ug/kg or hourly regimen24.
Platelet activating factor (PAF) modulation had been studied in
experimental acute Pancreatitis25. In trypsin injection and sodium
taurodeoxycholate models, Platelet activating factor is released into the
bloodstream peritoneal fluid, of rats13. PAF inhibition with an antagonist
accelerate its degradation and causes decrease inflammation resulting in
reductions in pro-inflammatory cytokines .
Andersson et al., 2007 in his study describe the usage of novel FVIIa
inhibiting agent which was investigated in an intraductal taurodeoxycholate
infusion model of AP16 .
Administration of and N-acetylcysteine and activesite inactivated FVII
given 90 minutes prior to AP induction causes a reduction in MPO levels in
distant organs like ileum and lungs and also reductions in plasma IL-6 levels
compared to saline which acts as controls when it occurs 6 hours after acute
pancreatitis induction.
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Bleeker et al in 1992 demonstrated that high dose Anti Thrombin -lll
had been tried in taurocholate induced pancreatitis in rat model 20which had
shown that there was improvement in survival rate. But Anti thrombin was
found to be ineffective in improving mortality20 in critically ill acute
pancreatitis patients.
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MATERIALS AND METHODS
Study Centre:
Department of Medical Gastroenterology, Madras Medical College
and Rajiv Gandhi Government General Hospital, Chennai
Duration of the Study:
1year
Study Design:
Prospective
Sample Size:
50 cases
Inclusion Criteria:
Patients who are admitted in Department of Medical and surgical
Gastroenterology and those patients admitted in other Medical and surgical
wards with History and investigations suggestive of Acute pancreatitis.
Exclusion Criteria:
• Patients not willing for study.
• Patients with known Haematological disorders.
• Patients with pre-existing or coexisting Chronic liver disease
• Pregnancy/Postpartum
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• H/o surgery in recent past
• Post ERCP pancreatitis
• Post infectious pancreatitis.
Patient selection and Data collection:
50 patients with clinical features of abdominal pain characteristic of
acute pancreatitis ,serum amylase and /or lipase3times upper limit of normal
and CT scan showing characteristic features of acute pancreatitis were chosen
and their Haematological and coagulation indices were studied prospectively
over a period of 1 year.
Methods:
Detailed clinical history of all 50 patients and thorough physical
examination of all 50 patients have been done.
Serum amylase/Lipase was done for all patients.
Liver function tests,Renal function tests,Xray chest PAview,Ultra
sonogram abdomen and contrast enhanced CT abdomen were done for all
patients to rule out various complications associated with acute pancreatitis.
Etiological workup was done for all 50patients with relevant
investigations.
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Patients were grouped into mild and severe pancreatitis by using
Balthazar CT scoring system and Modified CT severity index score.
Mild Pancreatitis – Balthazar CT score Grade- A,B,and C/ CT SI index6
Severe Pancreatitis - Balthazar CT score Grade –D and E,CTSI7
Presence of pleural effusion either unilateral or bilateral by chest
radiograph or CT scan correlates with severe pancreatitis. Haematological and
coagulation parameters are assessed for all patients .
Haematological indices :
1) Complete blood count which includes
Haemoglobin in gms%
Haematocrit in %
Total white blood cell count /cells in cu.mm
RBC count in millions/cu.mm
Differential count in %
ESR in mm/hr
Platelet count in cu.mm
Method of examining CBC :
Blood was drawn in EDTA containing test tube to prevent clotting.
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Automated haematology analyzer50:
Blood taken for examination is mounted on a rack after adequate
mixing. Different elements of the blood were analyzed by different
components of the instrument. Number and different cell types were analyzed
by cell counting compartment .Finally the computer review the results.
These analyzer machines aspirate only small volume of blood.
Aspiration is done through narrow tubing where sensors for counting the
number of cells located. These sensors can pick up the type of blood cells50.
Apart from counting and analyzing the white blood cells, Red blood
cells and platelets, these analyzers also measure the haemoglobin
concentration in blood and also within red blood cells.
1) Haematocrit :
The ratio of volume of erythrocyte to that of whole blood. It is
expressed in Percentage. The HCT may be measured directly by centrifugation
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with macromethods or micromethods, or indirectly as the product of the mean
corpuscular volume (MCV) times RBC count in automated instruments52. Here
the automated method is used.
2) Reticulocyte count : automated method.
Reticulocyte fractions are separated based on RNA content, with the
more immature cells containing the highest amount of reticulum. The
immature reticulocyte fraction (IRF) quantitatively describes the youngest
reticulocytes with the greatest staining intensity50.
It involves addition of stain such as new methylene blue and oxazine to
detect the RNA content of RBC.
3) Peripheral smear :
Steps : Examination of Wet preparation
Making and stain blood films-Polychrome methylene blue and eosin
(Wright’s) stain commonly used.
Coagulation Parameters :
Bleeding time and clotting time
Duke process of Bleeding time estimation
The patient was pricked, preferably on the ear finger tip or ear lobe
with a lancet , after alcohol swabbing . The prick should be roughly around
24
3–4 mm deep. Then with help of filter paper ,blood is wiped every 30seconds.
The test comes to an end when bleeding stops. The normal Bleeding time is
around 2–5 minutes52.
Clotting time:
5ml of blood is placed in a glass container, kept at body temperature and
observed .Normal clotting should occur in 5-15mts.
PT/INR :
Tissue thromboplastin (recombinant human or isolated animal tissue
factor) and patient plasma were incubated for several minutes, after which the
citrated plasma mixture is recalcified by the addition of excess CaCl2, and the
time required for clot formation is measured. The time to fibrin strand
formation is then measured automatically by photo optical device50.
The PT serves as the basis for the international normalized ratio (INR)
value which is used to monitor patients on warfarin. The INR is the ratio of
patient PT divided by geometric mean normal PT for the local laboratory
(based on a population of normal individuals assessed with identical
reagents,sample collection and machines), which is raised to the power of the
international sensitivity index. Although the INR is clearly the most
appropriate measure used in conjunction with oral anticoagulant monitoring,
for nonwarfarinized patient, actual PT values can also be used. In our study
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both PT and INR are used and INR is used in analysis with normal ratio of 0.9-
1.252. The PT measures the extrinsic coagulation pathway of coagulation,
which consists of activated FVII (FVIIa) and TF and proteins of the common
pathway (factors X, V, II, and fibrinogen)
Activated partial thromboplastin time :
A mixture of a negatively charged surface, phospholipid, and
anticoagulated patient plasma(3.2 g% sodium citrate) was incubated for
several minutes.. When whole blood is taken, the ratio of anticoagulant to
whole blood was 1 part anticoagulant to 9 parts whole blood. Patient’s plasma
is incubated with the above mixture for a particular time. Then the sample
was added with excess calcium chloride, and the clot formation time is
measured52. The APTT assesses the coagulation proteins of the so-called
intrinsic system and common pathways. This assay was commonly referred to
as the partial thromboplastin time (PTT), but it was actually an “activated”
PTT, in that its reagents contain a negatively charged surface which
accelerates the rate of the reaction. The APTT measures proteins of the
intrinsic coagulation system (FXII, prekallikrein, ,HMWK, FXI, FIX, and
FVIII) and proteins of the common pathway ( fibrinogen,factors X, V,and
II)52.
26
Fibrinogen :
Whenever the reason for prolongation of APTT or PT could not be
explained by any means, measurement of fibrinogen level is a valuable tool in
identifying the bleeding tendency.
• Fibrinogen assay can be 4 methods
• Clauss
• PT- derived Fibrinogen assays
• Immunological
• Gravimetric assays.
Clauss assay :
Procedure :
Reference plasma with known level of fibrinogen is calibrated with a
international standard in a series of dilution and a curve is constructed to create
a range of fibrinogen concentration .After that for each of the dilution,
clotting time is established and this is plotted on a log graph.When the
concentration is 1:10,it is equivalent to 100%50.
Thrombin and phospholipids are added to diluted plasma which is
deficient in platelets after adding up of calcium and incubated at temperature
of 35-37degree centigrade . The time taken for clot formation after adding up
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of calcium is compared with the curve and fibrinogen concentration is
deducted from that.
Fibrinogen degradation Product :
It is the protein fragment formed by the enzymatic reaction of plasmin
over fibrinogen and fibrin. It aids in detecting the degree of intravascular
coagulation. It also detect fibrinolysis when there is dissolution of fibrin in
clot50.
Test is done using latex agglutination assay.
Whole blood should be drawn into tube with Thrombin/Soybean trypsin
inhibitor for measuring this assay.
All these parameters were analysed with respect to severity of AP.
Data obtained by above methods were analysed by
1. SPSS 15
2. Chi square tests.
 Ethical committee approval obtained.
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OBSERVATIONS & RESULTS
Evaluation of the study subjects :
Observation:
The study subjects were evaluated according to their age and sex
distributions related to acute pancreatitis.
Table -1 Sex distribution :
Sex Frequency Percent
Male 44 88.0
Female 6 12.0
Total 50 100.00
The above table-1 shows 88% of acute pancreatitis patients were males when
compared to 12% in females .
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Table 2 - Age wise distribution of study subjects:
Age (Yrs) Frequency Percent
11-20 4 8.0
21-30 14 28.0
31-40 21 42.0
41-50 7 14.0
Above 50 4 8.0
Total 50 100.0
The above table -2 shows 42% of acute pancreatitis in 31-40 age group and
28% in 21-30 group. Rest of age group form just 30% in this study population.
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Table 3 :Etiology wise distribution of study subjects:
Etiology Frequency Percent
Alcohol 30 60.0
Gallstones 6 12.0
Hyper TGL 2 4.0
Idiopathic 12 24.0
Total 50 100.0
Table3 shows majority of patients were alcoholic (60%) in this study followed
by idiopathic group (24%) and gallstones(12%).
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Table 4 : Grade wise distribution of study subjects :
Grade of Severity Frequency Percent
Mild 18 36.0
Severe 32 64.0
Total 50 100.0
Table 4 shows 64%% of study subjects were in severe group and 36% in mild
group of acute pancreatitis.
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Table 5 : Haemoglobin levels distribution of study subjects:
Haemoglobin% Frequency Percent
Normal (>14 in M)
(>13 in F) 11 22.0
Low 39 78.0
Total 50 100.00
Table 5 shows Anaemia found in 78% of acute pancreatitis patients .
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Table 6: Total count levels distribution of study subjects:
Total WBC Count Frequency Percent
Normal 38 76.0
<4000 2 4.0
>11000 10 20.0
Total 50 100.00
Table 6 shows Leukocytosis was seen in 20% of study subjects and
leucopoenia found only in 4%.
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Table 7: Polymorph levels distribution of study subjects :
Polymorph% Frequency Percent
40-80% 35 70.0
<40% 1 2.0
>80% 14 28.0
Total 50 100.00
Table 7 shows Polymorph levels were higher in 28% of study population.
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Table 8 :Haematocrit levels distribution of study subjects:
HCT% Frequency Percent
40-45% 9 18.0
<40% 38 76.0
>45% 3 6.0
Total 50 100.00
Table 8 shows Haematocrit levels were lower in 76% of patients ,where
higher Haematocrit values seen only in 6%.
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Table 9 : Platelet count levels distribution of study subjects :
Platelet Count level Frequency Percent
1.5to 4lakhs 30 60.0
<1.5lakhs 17 34.0
>4lakhs 3 6.0
Total 50 100.00
Table 9 shows Low platelets were found in 34% and high platelets
observed in 6%.
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Table 10 : INR levels distribution of study subjects:
INR Frequency Percent
< 1.2 36 72.0
> 1.2 14 28.0
Total 50 100.0
INR levels were higher in 28% of study subjects.
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Table 11: APTT levels distribution of study subjects :
APTT Frequency Percent
24-36s 38 76.0
>36s 12 24.0
Total 50 100.0
Table 11 shows Increase in APTT levels in 24% of study population.
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Table 12: Fibrinogen levels distribution of study subjects:
Fibrinogen Frequency Percent
180-350mg/dl 23 46.0
<180 mg/dl 8 16.0
>350mg/dl 19 38.0
Total 50 100.0
Table 12 shows Increase in fibrinogen levels in 38% and decrease in
fibrinogen levels in 16%.
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Table 13: FDP levels distribution of study subjects :
FDP Frequency Percent
5µg/ml 42 84.0
>5µg/ml 8 16.0
Total 50 100.0
Table 13 shows Increase in FDP levels in 16% of study subjects.
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STATISTICAL ANALYSIS
Table- 1 Sex distribution in relation to Grade of acute pancreatitis
Sex Distribution
Grade
Total Significance
Mild Severe
Male
Count 15 29 44 Chi square
% within Sex 34.1% 65.9% 100.0% 0.580
% within Grade 83.3% 90.6% 88.0%
Female
Count 3 3 6 P>0.05
% within Sex 50.0% 50.0% 100.0% Not
significant
% within Grade 16.7% 9.4% 12.0%
Total
Count 18 32 50
% within Sex 36.0% 64.0% 100.0%
% within Grade 100.0% 100.0% 100.0%
Out of 44(88%) male patients ,29(90.6%) were in severe category and
15(83.3%) were in mild category.The observed difference between mild and
severe category were not statistically significant(P>0.05)
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Table 2- Age distribution in relation to grade of acute pancreatitis
Age Group in Years Grade Total Significance
Mild Severe
11-20
Count 1 3 4 Chi square
% within Age Group
in Years 25.0% 75.0% 100.0% 0.857
% within Grade 5.6% 9.4% 8.0% P>0.05
21-30
Count 4 10 14 Not
significant
% within Age Group
in Years 28.6% 71.4% 100.0%
% within Grade 22.2% 31.3% 28.0%
31-40
Count 9 12 21
% within Age Group
in Years 42.9% 57.1% 100.0%
% within Grade 50.0% 37.5% 42.0%
41-50
Count 3 4 7
% within Age Group
in Years 42.9% 57.1% 100.0%
% within Grade 16.7% 12.5% 14.0%
Above 50
Count 1 3 4
% within Age Group
in Years 25.0% 75.0% 100.0%
% within Grade 5.6% 9.4% 8.0%
Total
Count 18 32 50
% within Age Group
in Years 36.0% 64.0% 100.0%
% within Grade 100.0% 100.0% 100.0%
Out of 50 study subjects, 32(64%) in severe category and 18(36%) in mild
category. Patients belonging to age group from 11-40yrs presents more with
severe category than patients age above 40years.Inspite of dominance of
younger age group presenting with severe pancreatitis,the difference was not
statistically significant(P>.05).
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Table 3 Etiology wise distribution in relation to grade of pancreatitis:
Etiology
Grade
Total SignificanceMild Severe
Alcohol
Count 9 21 30 Chi square
0.725
% within Etiology 30.0% 70.0% 100.0%
P>0.05
Not
significant
% within Grade 50.0% 65.6% 60.0%
Gall
Stones
Count 3 3 6
% within Etiology 50.0% 50.0% 100.0%
% within Grade 16.7% 9.4% 12.0%
Hyper
TGL
Count 1 1 2
% within Etiology 50.0% 50.0% 100.0%
% within Grade 5.6% 3.1% 4.0%
Idiopathic
Count 5 7 12
% within Etiology 41.7% 58.3% 100.0%
% within Grade 27.8% 21.9% 24.0%
Total
Count 18 32 50
% within Etiology 36.0% 64.0% 100.0%
% within Grade 100.0% 100.0% 100.0%
Alcohol accounts for 70% of severe pancreatitis group .In contrast in gall
stone disease group 16.7% in mild group and 9.4% in severe group.But the
difference between variables were not statistically significant.
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Correlation of Haematological Parameters with Grade of pancreatitis :
Table 4:Haemoglobin variation with grade of Pancreatitis:
Hb
Grade
Total SignificanceMild Severe
Normal
(<14 in M)
(>13 in F)
Count 4 7 11
% within Hb 36.4% 63.6% 100.0% Chi sq test
% within Grade 22.2% 21.9% 22.0% 0.621
Low
Count 14 25 39
% within Hb 35.9% 64.1% 100.0%
P>0.05
Not
significant
% within Grade 77.8% 78.1% 78.0%
Total
Count 18 32 50
% within Hb 36.0% 64.0% 100.0%
% within
Grade
100.0% 100.0% 100.0%
Out of 50 study subjects, 32(78%) were anaemic in this study.But when these
anaemic patients were compared with grade of pancreatitis,64.1% were in
severe group and 35.9% in mild group the difference was not statistically
significant (P>.05).
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Table 5:Total Leukocyte count variation with grading of pancreatitis:
TC
Grade
Total Significance
Mild Severe
4000
- 11000
Count 16 22 38
% within TC 42.1% 57.9% 100.0% Chi square
% within Grade 88.9% 68.8% 76.0% 0.240
<4000
Count 0 2 2
P>0.05% within TC .0% 100.0% 100.0%
% within Grade .0% 6.3% 4.0%
>11000
Count 2 8 10
% within TC 20.0% 80.0% 100.0%
% within Grade 11.1% 25.0% 20.0%
Total
Count 18 32 50
% within TC 36.0% 64.0% 100.0%
% within Grade 100.0% 100.0% 100.0%
Only 10(20%) of study subjects have leukocytosis in this study. Leukocytosis
was found in 80% of severe type when compared with 20% of mild type.But
the percentage within grade is 25% in severe group and 11.1% in mild group.
Hence the difference was not statistically significant.
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Table 6 : Polymorphs distribution in relation with grade of Acute
pancreatitis:
Poly%
Grade
Total Significance
Mild Severe
40-80%
Count 13 22 35 Chi square
% within Poly% 37.1% 62.9% 100.0% 0.747
P>0.05
% within Grade 72.2% 68.8% 70.0%
<40%
Count 0 1 1 Not
significant
% within Poly% .0% 100.0% 100.0%
% within Grade .0% 3.1% 2.0%
>80%
Count 5 9 14
% within Poly% 35.7% 64.3% 100.0%
% within Grade 27.8% 28.1% 28.0%
Total
Count 18 32 50
% within Poly% 36.0% 64.0% 100.0%
% within Grade 100.0% 100.0% 100.0%
Increase in Polymorphs seen more in severe acute pancreatitis(64.3%) than in
mild acute pancreatitis (35.7%).But Polymorphs percentage within grade is
28.1% in severe acute pancreatitis and 27.8% in mild acute pancreatitis .Hence
the difference was not statistically significant.(P>0.05).
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Table 7 Haematocrit variation in relation with grade of acute pancreatitis:
HCT%
Grade
Total SignificanceMild Severe
40-45%
Count 3 6 9 Chi square
% within HCT% 33.3% 66.7% 100.0%
% within Grade 16.7% 18.8% 18.0% 0.976
<40%
Count 14 24 38 P>0.05
% within HCT% 36.8% 63.2% 100.0%
% within Grade 77.8% 75.0% 76.0% Not
significant
>45%
Count 1 2 3
% within HCT% 33.3% 66.7% 100.0%
% within Grade 5.6% 6.3% 6.0%
Total
Count 18 32 50
% within HCT% 36.0% 64.0% 100.0%
% within Grade 100.0% 100.0% 100.0%
Haemoconcentration (HCT>45%) which is a predictor of severe pancreatitis is
seen only in 6%.Majority of the study subjects have decreased haematocrit
values(76%).The difference was not statistically significant when the
haematocrit values are compared with grade of pancreatitis.(P>0.05).
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Table 8: Platelet count variation in relation to grade of pancreatitis:
Plt. Count
Grade
Total Significance
Mild Severe
Normal
Count 13 17 30 Chi square
% within Pl.Count 43.3% 56.7% 100.0% O.258
% within Grade 72.2% 53.1% 60.0% P>0.05
Low
Count 5 12 17
Not
significant
% within Pl.Count 29.4% 70.6% 100.0%
% within Grade 27.8% 37.5% 34.0%
High
Count 0 3 3
% within Pl.Count .0% 100.0% 100.0%
% within Grade .0% 9.4% 6.0%
Total
Count 18 32 50
% within Pl.Count 36.0% 64.0% 100.0%
% within Grade 100.0% 100.0% 100.0%
Thrombocytopenia is observed in 17 study subjects (34%) in this study. In
these 17 patients, 12(70.6%) were in severe group and 5 (29.4%) in mild
group. But percentage of thrombocytopenia within the grade was 37.5% in
severe group and 27.8% in mild group and hence the differences was not
statistically significant(P>0.05).
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Table 9 : INR variation in relation to grade of acute pancreatitis:
INR
Grade
Total Significance
Mild Severe
<1.2
Count 13 23 36 Chi square
% within INR 36.1% 63.9% 100.0% 0.979
% within Grade 72.2% 71.9% 72.0% P>0.05
>1.2
Count 5 9 14
Not
significant
% within INR 35.7% 64.3% 100.0%
% within Grade 27.8% 28.1% 28.0%
Total
Count 18 32 50
% within INR 36.0% 64.0% 100.0%
% within Grade 100.0% 100.0% 100.0%
14 (28%) study subjects showed Increase in INR values in this study. In this
14 study subjects 9 (64.3%) were in severe group and 5(35.7%) in mild group.
But percentage of increase INR within grade was 28.1% in severe category
and 27.8% in mild category and hence the difference was not statistically
significant. (P>0.05)
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Table 10 :APTT variation in relation to grade of acute pancreatitis :
INR
Grade
Total Significance
Mild Severe
Normal
Count 16 22 38 Chi square
% within APTT 42.1% 57.9% 100.0% 0.109
% within Grade 88.9% 68.8% 76.0% P>0.05
High
Count 2 10 12
Not
significant
% within APTT 16.7% 83.3% 100.0%
% within Grade 11.1% 31.3% 24.0%
Total
Count 18 32 50
% within APTT 36.0% 64.0% 100.0%
% within Grade 100.0% 100.0% 100.0%
12 (24%) of study subjects have high APTT value and the value is more in
severe pancreatitis group (83.3%) than in mild group (16.7%).But the
percentage within the grade was 31.3% in severe group and 11.1% in mild
group and the differences was not statistically significant.( P>0.05)
51
Table 11 : Fibrinogen variation in relation to grade of acute pancreatitis :
Fibrinogen
Grade
Total Significance
Mild Severe
Normal
Count 9 14 23 Chi Square
% within Fibrinogen 39.1% 60.9% 100.0% 0.313
% within Grade 50.0% 43.8% 46.0% P>0.05
Low
Count 1 7 8
Not
significant
% within Fibrinogen 12.5% 87.5% 100.0%
% within Grade 5.6% 21.9% 16.0%
High
Count 8 11 19
% within Fibrinogen 42.1% 57.9% 100.0%
% within Grade 44.4% 34.4% 38.0%
Total
Count 18 32 50
% within Fibrinogen 36.0% 64.0% 100.0%
% within Grade 100.0% 100.0% 100.0%
Out of 50 patients low fibrinogen observed in 8 (16%) and high fibrinogen
observed in 19(38%) clients. Majority of low fibrinogenemia belongs to severe
category (87.5%). Increase in fibrinogen levels are observed in
11(57.9%)patients in severe category and 8(42.1%)patients in mild category.
The percentage difference between the above variables within grade was not
statistically significant.(P>0.05)
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Table 12: FDP variation in relation to grade of acute pancreatitis :
FDP
Grade
Total Significance
Mild Severe
Normal
Count 18 24 42 Chi square
% within FDP 42.9% 57.1% 100.0% 0.021
% within Grade 100.0% 75.0% 84.0% P<0.05
High
Count 0 8 8 Significance
at 5%
% within FDP .0% 100.0% 100.0%
% within Grade .0% 25.0% 16.0%
Total
Count 18 32 50
% within FDP 36.0% 64.0% 100.0%
% within Grade 100.0% 100.0% 100.0%
High level of FDP observed in 8(16%) patients and all 8 cases were observed
in severe category. Hence the difference between 2 grades were statistically
significant (P<.05).
53
Table 13: Cross tabular variation between APTT and fibrinogen :
APTT
Fibrinogen
Total
Significanc
eNormal Low High
Normal
Count 20 4 14 38 Chi square
% within APTT 52.6% 10.5% 36.8% 100.0% 0.104
% within
Fibrinogen
87.0% 50.0% 73.7% 76.0% P>0.05
High
Count 3 4 5 12
Not
significant
% within APTT 25.0% 33.3% 41.7% 100.0%
% within
Fibrinogen
13.0% 50.0% 26.3% 24.0%
Total
Count 23 8 19 50
% within APTT 46.0% 16.0% 38.0% 100.0%
% within
Fibrinogen
100.0% 100.0% 100.0% 100.0%
This table shows that 4patients(33.3% within APTT) had rise in APTT
value and decrease in fibrinogen.These patients can be considered as full
blown DIC. 4 patients (50% within fibrinogen) have decrease in fibrinogen
values but normal APTT values. These patients were early in development of
DIC.The difference between 2 variables were not statistically significant
(P>0.05).
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Table 14: Cross tabular variation between APTT and FDP
APTT
FDP
Total Significance
Normal High
Normal
Count 33 5 38 Chi square
% within APTT 86.8% 13.2% 100.0% 0.329
% within FDP 78.6% 62.5% 76.0% P>0.05
High
Count 9 3 12
Not
significant
% within APTT 75.0% 25.0% 100.0%
% within FDP 21.4% 37.5% 24.0%
Total
Count 42 8 50
% within APTT 84.0% 16.0% 100.0%
% within FDP 100.0% 100.0% 100.0%
This table shows 3 patients(25%within APTT) have both High APTT
value and High FDP values indicative of DIC in these patients. 5 patients
(62.5%within FDP) have High FDP values but normal APTT values,
indicating that these patients were in early severe pancreatitis and feature
suggestive of impending DIC. The difference between these two variables
were not statistically significant.(P>0.05)
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Table 15: Cross tabular variation between FDP and fibrinogen
FDP
Fibrinogen
Total
Significanc
eNormal Low High
Normal
Count 21 6 15 42 Chi square
% within FDP 50.0% 14.3% 35.7% 100.0% 0.416
% within
Fibrinogen
91.3% 75.0% 78.9% 84.0% P>0.05
High
Count 2 2 4 8
Not
significant
% within FDP 25.0% 25.0% 50.0% 100.0%
% within
Fibrinogen
8.7% 25.0% 21.1% 16.0%
Total
Count 23 8 19 50
% within FDP 46.0% 16.0% 38.0% 100.0%
% within
Fibrinogen
100.0% 100.0% 100.0% 100.0%
This table shows 2 patients(25%within FDP) have low fibrinogen levels
and High FDP levels indicative of full blown DIC. 6 patients (75% within
fibrinogen) have low fibrinogen values but normal FDP values implies these
patients were in impending DIC.The difference between these 2 variables were
not statistically significant(P>0.05).
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DISCUSSION
Haematological and coagulation changes have been reported in acute
pancreatitis as evidenced by Benjamin et al and Inner field et al in 1952,who
did their study on coagulation changes in acute pancreatitis8 and J.E . Trapnel
et al in 1966 in journal of annals of Royal college of surgeons,England did
study on Haematological changes in acute pancreatitis1 and he reported drop
in value of haematocrit and haemoglobin values and also reported significant
leukocytosis in his study.
Acute Pancreatitis produces a severe inflammatory response which is
mainly responsible for acinar cell damage which leads to release of
inflammatory mediators like cytokines,TNF and PAF thereby resulting in a
systemic inflammatory response3.
These inflammatory mediators alter the normal hemostatic mechanism
by acting in paracrine or autocrine loops to activate the monocytes,neutrophils
to site of injury and these activated cells inturn expresses the tissue factor in
the injured pancreatic cell and alter the coagulation pathway8 .
The Hypothesis states that these coagulation changes may be due to
early consumption of coagulation factors which are secondary to enzymes of
pancreas , especially trypsin , or it may be secondary to vascular injury5.
57
Hence recognition of these haematological and coagulation disturbance
at earliest is essential especially disseminated intravascular coagulation to
improve the outcome in patients with acute pancreatitis.
In this study, patients were graded in to mild and severe pancreatitis
by Balthazar CT grade system/CTSI scoring system. After satisfying the
inclusion and exclusion criteria , Haematological and coagulation changes
were assessed in reference to these 2 grades.
Literature research showed that haematological abnormalities in acute
pancreatitis were recorded in a prospective study by Desmond Murphy and
Clement Imrie.
In another study by Li-Pe cheng ,he studied the influence of coagulation
function on acute pancreatitis on 56 patients of acute pancreatitis with normal
control group and found that the coagulation parameters were significantly
increased indicating bad prognosis though the difference between the 2 groups
were not statistically significant. In our study we found similar coagulation
changes.
In our study, majority ( 88% )were male patients and most of patients
belong to middle age group 28% and 42% for 21-30 and 31-40 age group
respectively. The male predominance is due to the etiological factor which is
alcohol abuse constituting about 60% of the study group. Though gall stones
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are the next common etiological factor next to alcohol, in our study it
constitutes about 12% only.
64% of patients belonged to severe pancreatitis group and 36%
belonged to mild pancreatitis group. The haematological parameters and
coagulation parameters were correlated with the 2 grades of acute pancreatitis
and analyzed.
Haemoconcentration (HCT>45%) is a sign of severe acute
pancreatitis39. However this was found only in 6% of our study group, where
as decrease in haematocrit value were noted in 76%. This is due to the fact
majority of patients in study group were anaemic.The Patients in our study
group had haemoglobin level ranging from 6-12gms%.However the
corresponding haematocrit was appreciably higher in most of the patients in
severe acute pancreatitis indicating haemoconcentration.
Leukocytosis was noted in 20% of study group and they are found more
(80%) in severe acute pancreatitis. Polymorphs were higher in 64.3% in severe
group and 35.7% in mild acute pancreatitis.Although neutrophilic dominance
is noted in 28 out of 32 patients with severe acute pancreatitis.4 had significant
lymphocytosis affecting the P value . This is probably due to subclinical viral
infection. Though these variables were more in severe pancreatitis,the
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difference between these variables between mild and severe group were not
statistically significant(P>0.05).
Thrombocytopenia was noted in 34% of study group,of which 70.6%
were belong to severe acute pancreatitis.Thrombocytopenia could be due to a)
a part of DIC with associated global prolongation of coagulation parameters or
b) manifestation of thrombotic microangiopathy resulting from diffuse
endothelial injury and platelet activation.
Prothrombin time was found to be increased in 28% of patients and
was seen more in severe acute pancreatitis group(64.3%).Similarly increase
in APTT values were seen in 24%,of which 83.3% were in severe pancreatitis
group.
Fibrinogen levels were lower in 16% of study group, of which 87.5%
was in severe pancreatitis group. These patients were in severe DIC. High
fibrinogen values were seen in 38% ,of which severe pancreatitis accounts to
57.9%.These patients were in early stage of the disease and did not have frank
haemostatic disturbance. This increased fibrinogen value in 38% of patients
can be explained by the fact that fibrinogen is a acute phase reactant like CRP
,and hence can be increased with severe inflammation. Though these
variables were more in severe pancreatitis,the difference between these
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variables between mild and severe group were not statistically
significant(P>0.05).
In contrast FDP levels were found to be higher in 16% of study group
and all of them belong to severe group of pancreatitis. Hence the difference
between these variables between mild and severe group were statistically
significant (P<0.05%).
Cross tabulation done between APTT and fibrinogen values showed that
4patients(33.3% within APTT) had rise in APTT value with decrease in
fibrinogen values .These parameters could indicate DIC in these patients. 4
patients (50% within fibrinogen) have decrease in fibrinogen values but
normal APTT values. These patients can be early in development of DIC and
these patients should receive more attention for better clinical outcome.
Similarly when cross tabulation was done between APTT and FDP,
3 patients(25%within APTT) have increased values of both APTT and FDP
indicating DIC whereas 5 patients(62.5%within FDP) with high FDP value
had normal APTT values.These patients presented in the early stage of severe
acute pancreatitis and were probably with compensated DIC.Timely
correction could avert progress to full blown DIC.
When fibrinogen and FDP was cross tabulated, 2 patients(25%within
FDP) have features of full blown DIC with decrease in fibrinogen value and
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increase in FDP values. 6 patients (75% within fibrinogen) have low
fibrinogen values but with normal FDP values. Out of these 6 patients 5 were
in severe category .It has been observed that the fibrinogen levels vary
significantly in the first week of acute severe pancreatitis. Fibrinogen
synthesis and lysis go hands together in acute pancreatitis depending on the
inflammatory response.The natural anticoagulants (protein-C,AT-111) are also
variably upregulated and downregulated by the acute phase reactants,
essentially working against thrombosis. The fibrinogen and FDP values are
therefore significantly influenced by inflammatory cytokines with variable
thrombohaemorrhagic manifestations53.
Though these crosstabulation variables with APTT,fibrinogen and FDP
give clue about DIC and impending DIC developing in these patients, the
difference between these variables between mild and severe group were not
statistically significant(P>0.05).
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CONCLUSION
The study titled Prospective study on haematological and coagulation
changes in acute pancreatitis was conducted in 50patients in Madras Medical
college and Rajiv Gandhi Government general hospital,Chennai and following
conclusions were made.
1. Haematological and coagulation abnormalities were more common in
severe acute pancreatitis.
2. Though evidence of full blown Disseminated Intravascular Coagulation
is seen in few patients, the cases which were impending Disseminated
Intravascular Coagulation and cases which have high potential to
develop Disseminated Intravascular Coagulation were recognised and
could be managed effectively.
3. The difference between variables comparing haematological and
coagulation indices with severity of pancreatitis were not statistically
significant except for the increase in FDP value which was statistically
significant .
4. Therapeutic regimens like Activated protein C ,Anti thrombin
111,Platelet activating factor modulating agents, Factor V11a inhibitors
could be tried in near future to improve the clinical outcome of patients
with severe coagulatory disturbance in acute pancreatitis.
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PROFORMA
Prospective study of Haematological and coagulation changes in Acute
pancreatitis
Name: Age: Sex:
Address: Occupation:
Symptoms
• Abdominal pain
• vomiting
• abdominal bloatness
• abdominal distension
• Loss of appetite
• Weight loss
Past history:
• Diabetes mellitus
• Hypertension
• Previous h/o pancreatitis
Personal history:
• Smoking Alcoholism
General examination::
Pulse:
  
BloodPressure:
Systemic Examination:
CVS: RS: Abdomen: CNS:
Investigations:
Blood : Urine:
Haemoglobin Albumin
Hematocrit sugar
Total count Deposit
Differential count Motion :
RBC count ova,cysts
Reticulocyte count Chest X ray PA view
Peripheral smear. ECG all leads
Platelet count Ultrasonogram
abdomen
ESR CECT Abdomen
Bleeding time
Clotting time
Prothrombin time/INR
Acitivated partial Thromboplastin time
Fibrinogen
Fibrinogen degradation Product
  
SerumAmylase
Serum Lipase
Fasting Lipid profile
Serum Calcium
Serum Phosphorus
Renal Function tests
Liver function tests
Sl 
No
Name Age/Sex G.E.No S.Amylase U/L
S.Lipase 
U/L
CECT abd chest Xray Etiology
Modified CTSI/ 
Balthazar score
Grade
1 Mohan 39/M 1427/12 238 168 pesudocyst pancreas/inflammed pancreas B/L PL.E Alcoholic CTSI-7/Gr D Severe
2 Tamilselvan 16/m 1462/12 346 264 pesudocyst pancreas Lt Pl.E Idiopathic CTSI-6/Gr D Severe
3 Manikandan 19/M 1764/12 1112 678 Ascites/edematous pancreas Lt Pl.E Idiopathic CTSI-6/Gr D Severe
4 Babu 25/M 1843/12 521 161 Pesudocyst tail pancreas/bulky pancreas Normal Alcoholic CTSI-6/Gr D severe
5 Ponnusamy 34/M 1368/12 348 210 Peripancreatic fat stranding Normal Alcholic CTSI-3/GrC Mild
6 Malliga 40/F 1945/12 144.5 363.8 Bulky&edematous pancreas/fat stranding Normal gallstones CTSI-2/GrC Mild
7 Govindaraj 35/M 1398/12 538 184 Bulky pancreas/pseudocyst head &body Rt PL.E/Pe.E Alcoholic CTSI-7/Gr D Severe
8 Chakravarthy 35/M 2025/12 288 168 Bulky pancreas/collection pancreas head Lt Pl.E Alcoholic CTSI-7/Gr D Severe
9 Devi 28/F 1547/12 370 740 Bulky pancreas Normal Hyper TGL CTSI-2/GrB MIld
10 Prabhu 32/M 888/13 734 362 enlarged gland/Peripancreatic fat strand Lt pl.E Alcoholic CTSI-7/Gr D Severe
11 Sakunthala 55/F 1212/13 1369 344 Edematous pancreas/fluid collection head pancreas Lt PL .E Gallstones CTSI-7/Gr D severe
12 Bhagyaraj 28/M 1324/13 380 264 Pseudocyst tail/Lt psoas abscess Lt PL .E Alcholic CTSI-8/GrE severe
13 Ramesh 36/M 1892/12 368 520 Pseudocyst pancreas head and body Rt PL.E Alcoholic CTSI-7/Gr D severe
14 Kandasamy 30/M 1648/12 282 384 fluid collection head pancreas Rt PL.E alcoholic CTSI-7/Gr D severe
15 Mani 39/M 1005/13 332 374 Bulky&inflammed pancreas Normal Idiopathic CTSI-3/GrC mild
16 ranjith 27/M 890/13 216 450 fluid collection tail pancreas Lt PL .E Idiopathic CTSI -6/Gr D Severe
17 Sivashankar 24/M 1693/12 213.8 360.8 Pseudocyst pancreatic tail ,neck & liver Lt Pl.E Idiopathic CTSI-7/Gr D Severe
18 Adimoolam 38/M 1836/12 243 151.7 enlarged gland/Peripancreatic fat strand Normal Alcoholic CTSI-3/GrC mild
19 Dhanasekar 47/M 1114/13 146 220.8 enlarged gland/Peripancreatic fat strand Normal Alcoholic CTSI-3/GrC mild
20 Rajagopal 62/M 1323/13 226 320.8 body&tail bulky with peripancreatic fat stranding B/L PL.E Alcoholic CTSI-7/Gr D Severe
21 Shankaraiah 48/M 1114/13 182 470 pseudocyst body and tail Lt PL.E Alcoholic CTSI-8/GrD Severe
22 Thimmaram 37/M 1674/13 1340 7350 Bulky pancreas/choledocholithiasis Rt PL.E Gall stone CTSI-7/Gr D Severe
23 Abdul majith 49/M 2122/13 197.86 169.2 Pseudocyst pancreas head/bulky edematous Lt Pl.E Alcoholic CTSI-7/Gr D Severe
24 Nagamuthu 47/M 2094/13 115.48 139 Bulky pancreatic head/peripancreatic fat strands Normal Alcoholic CTSI-3/GrC mild
25 Gopinath 31/M 1387/12 222 184 Bulky pancreas Normal Alcoholic CTSI-3/GrC mild
26 Janarthanan 48/M 1098/13 535 380 Bulky pancreas/ascites Lt Pl.E Alcoholic CTSI-6/Gr D Severe
27 Harikrishnan 54/M 1849/12 1425.4 412 Pseudocyst head& uncinate process Lt PL.E Alcoholic CTSI-7/Gr D severe
28 Devaraj 45/M 2056/13 1834 294 Marginal irregularity head&uncinate pancreas Rt PL.E Idiopathic CTSI-3/GrC mild
29 Saravanan 28/M 1486/12 354 627 Edematous pancreas B/L PL.E Alcoholic CTSI-6/Gr D severe
30 Manikandan 14/M 1406/12 3174 295 Edematous pancreas Normal Idiopathic CTSI-3/GrB mild
31 Allimuthu 28/M 1308/13 398 340 edematous pancreas/peripancreatic fat stranding Normal Idiopathic CTSI-3/Gr C mild
32 Prakash 29/M 1108/13 365 3678 edematous pancreas/peripancreatic fat stranding Lt PL.E alcoholic CTSI-7/Gr D severe
33 Moorthy 34/M 468/13 119 256 Psuedocyst body and tail Rt Pl.E Alcoholic CTSI-7/Gr D severe
34 Elango 31/M 2147/12 251 158 Bulky pancreas /Peripancreatic fluid collections Lt Pl.E Alcoholic CTSI-7/Gr D severe
35 Ramesh 38/M 1597/12 600 258 edematous pancreas/calculus in GB Normal Gall stone CTSI-3/Gr C mild
36 Varadharajan 51/M 2118/12 1579 327 edematous pancreas/peripancreatic fat stranding normal Idiopathic CTSI-4/GrC mild
37 Vinoth 30/M 1892/12 354 226 stones in GB & CBD/peripancreatic fat stranding Normal Gall stone CTSI-4/GrC mild
38 Anand 25/M 2008/13 4231 252 bulky pancreas/pancreatic ascites Lt Pl.E Idiopathic CTSI-6/Gr D severe
39 Rajesh 22/M 1643/13 243 182 Bulky and edematous pancreas Normal alcoholic CTSI-3/Gr C mild
40 Anandhan 38/M 1204/13 147 176 bulky pancreas/peripancreatic fat stranding Normal Idiopathic CTSI-3/GrC mild
41 Shakunthala 32/F 1311/13 228 426.4 edematous pancreas/peripancreatic fat stranding B/L PL.E Idiopathic CTSI-7/Gr D severe
42 Karunakaran 39/M 1845/12 102 144 bulky pancreas/peripancreatic fat stranding B/L PL.E Alcoholic CTSI-7/Gr D Severe
43 Kashif 18/M 1074/13 168 282 Pseudocyst Head of pancreas Lt Pl.E Idiopathic CTSI-6/Gr D Severe
44 Sampath 47/M 2114/12 542 468 pseudocyst body and tail Lt PL.E Alcoholic CTSI-7/Gr E Severe
45 Kavitha 32/F 1809/12 282 346 Fluid collection in peripancreatic region/lesser sac Lt Pl.E Hyper TGL CTSI-8/GrE Severe
46 Pushpa 36/F 1467/12 144 382 Bulky and edematous pancreas Normal Idiopathic CTSI-3/GrB mild
47 Saravanan 38/M 1348/12 118 260 Peripancreatic fat stranding Normal Alcoholic CTSI-4/GrC mild
48 Manikandan 28/M 1690/13 230 990 bulky pancreas with peripancreatic fluid 
collectionNormal
Lt Pl.E Alcoholic CTSI-7/GrD severe
49 Prabhakaran 39/M 1963/12 210 260 emphysematous pancreatitis/distal CBD calculus B/L PL.E gallstone CTSI-7/GrD severe
50 Vadivel 29/M 2204/12 528 416 Peripancreatic fat stranding/pseudocyst head Lt Pl.E Alcoholic CTSI-6/Gr D severe
Sl 
No
Name Age/Sex G.E.No Hb gm% TC in % DC in %
HCT in 
%
ESR 1hr
RBC count 
Mill/cu mm
Pl.count 
Lakh/cumm
Reticulocyte 
count
Peripheral smear BT CT PT/INR APTT secs
Fibrinogen 
mg/dl
FDP µg/ml
1 Mohan 39/M 1427/12 8.9 10,700 P90L7E3 27 40 3.4 2.07 1.50% N N 2mts 40s 6mts 15s 15.5/1.12 37 741 5
2 Tamilselvan 16/m 1462/12 9.8 2 700 P68L32 32% 36 4.3 78,000 0.20% M H 2mt 5mts 10s 14/1.0 26.5 324.8 <5
3 Manikandan 19/M 1764/12 6.6 18,150 P76L20E4 28% 45 5.11 4.08 0.40% MH 2mts 10s 5mts 12.2/1.15 33.7 364.7 10
4 Babu 25/M 1843/12 11.1 3800 P70L27E3 34 20 4 93000 0.50% NN 3mt 20s 6mt 15s 16.5/1.56 28.2s 368.2 5
5 Ponnusamy 34/M 1368/12 10.3 10,200 P80L18E2 30 34 3.56 2.60lakhs 2% MH 2mts 30s 6mts 30s 16.0/1.5 37.9s 224.4 <5
6 Malliga 40/F 1945/12 11.9 15,800 P96L6E2 35 20 4.35 3.18 0.30% NN with MH 3mts 20s 7mts 20s 12.3/0.88 30.3s 450 5
7 Govindaraj 35/M 1398/12 8 12,900 P80L12 E8 25 40 2.55 4.07 0.50% MH 3mts45s 5mts 30s 13.7/0.98 49.2 382 5
8 Chakravarthy 35/M 2025/12 10.2 7 300 P73L1E12 30 26 3.48 3.76 0.80% NNwith MH 3mts 20s 5mts 15s NC NC 397 >5
9 Devi 28/F 1547/12 9.6 8,000 P51L47E2 30 42 3.7 95000 0.10% MH 2mt 10s 3mts45s 12.2/1 27.2s 324.6 <5
10 Prabhu 32/M 888/13 6 16,800 P88L7E5 17 62 3.14 2.03 0.50% MH/leukocytosis 
toxic gran/↑↑Pl
3mts 15s 5ts 45s 12.6/1.08 35s 380.7 5
11 Sakunthala 55/F 1212/13 11.3 5,200 P70L29E1 36 25 4.2 2.37 0.70% MH/atyp Lymp 1mt30s 7mt15s NC NC 103.5 5
12 Bhagyaraj 28/M 1324/13 8 14 200 P85L10E5 32 26 3.37 3.11 1.00% MH 2mts 30s 6mts 20s 14.3/1.11 42.3 505.6 5
13 Ramesh 36/M 1892/12 9 8,900 P87L9E4 27 34 3.37 1.3 0.80% NN 3mts 20s 5mts40s 12.6/1.08 28 186.4 <5
14 Kandasamy 30/M 1648/12 14.3 9,100 P60L36E4 42 8 4.33 2.24 0.70% MH 3mts 40s 6mts 20s 16.0/1.5 36 184.2 >5
15 Mani 39/M 1005/13 13.2 6 200 P62L30E8 39 5 3.38 3.16 0.80% NN 2mts 40s mts 30s 15.0/1.36 33 398 <5
16 ranjith 27/M 890/13 14.5 13,610 P85L12E3 42.4 6 5.1 2.45 0.80% NN mild Leu ↑ 1mt 30s 4mts10s 14.9/1.34 38.2 320.3 <5
17 Sivashankar 24/M 1693/12 4.5 5,500 P60L33E7 42 4 5.11 2.91 0.10% Normal 1mt 33s 2mt44s 12.2/1.0 29.0s 207 5
18 Adimoolam 38/M 1836/12 8.9 4,900 P90L8E2 42 42 2.99 1.88 0.80% Normal 2mt 07s 3mt 12s 12.6/1.08 36 320.8 <5
19 Dhanasekar 47/M 1114/13 9 10,200 P57L41E2 30 22 4.2 1.44 0.50% NN 3mts 08s 6mts 30s 16.5/1.56 42.3 690.7 5
20 Rajagopal 62/M 1323/13 11 9,500 P75L22 E3 33 22 3.48 80,000 0.80% MH/aty Lymp 1mt 48s 4mt20s 12.2/1 35s <50 5
21 Shankaraiah 48/M 1114/13 10.6 15,200 P80L18E2 34 22 3.7 4.21 0.50% NN with MH 2mt 30s 5mt40s 16.0/1.5 34s 342 <5
22 Thimmaram 37/M 1674/13 12.6 7,800 P81E2B1L16 29.7 50 5.12 92,000 0.80% NN ,Target cells 2mt 30s 3mt50s 22.2/2.05 46.2 93 5
23 Abdul majith 49/M 2122/13 12 9,200 P67L26E7 26 68 4.26 1.8 0.80% NN 1mt 10s 3mt50s 14.3/1.11 39.2 179.5 10
24 Nagamuthu 47/M 2094/13 8.4 11,000 P70L25E5 26 46 5.36 2 0.50% NN with MH 1mt10s 3mt 20s 12.6/1.08 28.5 320 <5
25 Gopinath 31/M 1387/12 9.6 9,800 P51L45E4 32 42 3.46 1.82 0.80% NN with MH 3mt 15s 5mt40s 12.6/1.08 32.4 126.2 <5
26 Janarthanan 48/M 1098/13 13.9 7,700 P70L27E3 38.2 9 3.92 3 0.80% MH 1mt52s 3mts20s 12.2/1.0 36s 316.8 <5
27 Harikrishnan 54/M 1849/12 4.6 5,500 P70L22E8 15 28 2.24 2.06 0.70% NN 2mt 30s 5mts 30s 12.6/1.08 34s 282.8 >5
28 Devaraj 45/M 2056/13 14.6 14,300 P79L11E1 41.7 20 4.29 254,000 0.80% MH 3mts 30s 4mts 20s 14.3/1.11 36 182.3 <5
29 Saravanan 28/M 1486/12 14.7 10,600 P90L8E2 43 10 5.54 1.19 0.70% NN mild Leu ↑ 3mts 40s 5mts 30s 14.9/1.34 30 282.4 5
30 Manikandan 14/M 1406/12 8.5 11,100 P70L25E5 26 42 3.86 2 0.80% MH 3mts 45s 5mts 20s 12.6/1.08 32 380.6 <5
31 Allimuthu 28/M 1308/13 16.8 10,200 P88L6E6 50 10 6.06 1.45 0.70% NN MH 4mts 6mts 12.6/1.08 36s 383.2 5
32 Prakash 29/M 1108/13 12 7,100 P35L60E7 36.6 46 4.52 3 0.80% NN mild Leu ↑ 3mts 10s 5mts 10s 14.3/1.11 38s 342.5 <5
33 Moorthy 34/M 468/13 15.4 7,600 P70L28E2 49 28 4.66 1.22 0.50% Normal 3mts15s 6mts 15s 14.2/1.11 36 124 <5
34 Elango 31/M 2147/12 13.4 6,700 P80L19E1 40 20 5 2 0.60% Normal 2mts 07s 5mts 12s 12.2/1.0 28 128.2 <5
35 Ramesh 38/M 1597/12 11.7 7,500 P87L11E2 35 26 3.75 1.27 0.80% MH 3mts 20s 4mts 20s 12.6/1.08 30 324.2 <5
36 Varadharajan 51/M 2118/12 14.5 9,300 P77L15E8 36 35 4.56 3 0.80% NNwith MH 3mts 08s 6mts 20s 15.0/1.36 32s 362.4 5
37 Vinoth 30/M 1892/12 10.9 5,800 P75L20E5 35 25 3.6 3.1 0.70% MH 3mts24s 5mts 30s 14.9/1.25 33.6 380.4 5
38 Anand 25/M 2008/13 11.8 10,900 P87L6E3 35 30 4.39 1 1.50% NN 4mts20s 6mts 20s 14.3/1.11 30s 383.2 5
39 Rajesh 22/M 1643/13 18.8 5,100 P70L26E4 42 8 5.03 1.43 0.50% NN 1mt 40s 3mts 20s 12.6/1.08 36 268.4 <5
40 Anandhan 38/M 1204/13 12.3 11,000 P87L10E3 36 15 3.87 3 1.00% NN 2mt 13s 4mts38s 12.3/0.88 32.4s 362.4 <5
41 Shakunthala 32/F 1311/13 8.7 11 500 P68L26E6 27 22 4.22 1.01 0.80% MH Aty Lym/eos 1mt 30s 7mts15s 16.0/1.5 38s s 103.5 >5
42 Karunakaran 39/M 1845/12 10.5 6,900 P60L38E2 33 25 3.88 2 0.50% NN 1mt40s 3mt 49s 12.8/1.16 36s 328 <5
43 Kashif 18/M 1074/13 14 8,300 P81L17E2 42 8 5.2 1.57 0.60% MH 2mts 32s 4mts 28s 12.6/1.08 34.8s 382 5
44 Sampath 47/M 2114/12 16 7,000 P59L35E6 48 4 4.88 2 0.70% NN 1mt45s 5mts 35s 14.3/1.11 36s 278 <5
45 Kavitha 32/F 1809/12 12.8 4,000 P64l26 E10 42 18 3.9 30000 0.30% MH 1mt 20s 3mt 40s 12.2/1.0 32 435 20
46 Pushpa 36/F 1467/12 9.4 5 300 P60L35E5 35 20 4.2 3 0.20% MH 2mts 30s 4mts 20s 14.3/1.11 36 326 <5
47 Saravanan 38/M 1348/12 8.98 5,700 P71L26E3 29 28 3.9 2.65 0.60% NN 2mt10s 4mts 30s 12.6/1.08 32.2s 286.8 <5
48 Manikandan 28/M 1690/13 12.4 5,200 P40L54E6 37 8 4.08 3 0.20% MH/Plt↑ 1mt15s 3mts 40s 14.5/1.04 26.4s 321.4 <5
49 Prabhakaran 39/M 1963/12 10.2 6,360 P67L30E3 28 32 3.24 1.16 0.50% NN 2mts 30s 4mts 20s 15.3/1.10 16.6 613.7 10
50 Vadivel 29/M 2204/12 8.7 15,900 P80L8E2 26 30 3.86 86,000 0.50% MH 3mts 20s 6mts 20s 14.3/1.1 24.8 320.8 <5
  
eysfor Master Chart
Normal Values
Haemoglobin - Men : 14+ Female 13+
Total Count - 4000 to 11000
Differential Count - Polymorph : 40-80% Lymphocytes : 20-40%
Monocytes : 2-10% Eosinophils : 1-6%
Basophils : <2%
Haematocrit - 40-45%
Platelet Count - 1.5 to 4 lakhs
ESR - >15
Recticulocyte count - <1.5%
Prothrombin Time - >3 sec.
INR - >1.2
Fibrinogen - 180-350
FDP - <5
Abbreviation of Master Chart
Peripheral Smear - MH-Microcytic Hypochromic
NN - Normocytic Normochromic
Pl.E - Pleural Effusion.
CTSI - Computerised tomography severity index
GE.No - Gastroenterology number
  

  

  

  
 INFORMATION SHEET
• We are conducting a prospective study on haematological and
coaguation changes in acute pancreatitis in patients admitted in the ward
at Rajiv Gandhi Government &general hospital with clinical features
and investigations suggestive of acute pancreatitis.
• The purpose of the study is to analyze the haematological and
coagulation changes in acute pancreatitis who are admitted with clinical
features and investigation suggestive of acute pancreatitis and
correlating the changes to its severity .
• The privacy of the patients in the research will be maintained throughout
the study. In the event of any publication or presentation resulting from
the research, no personally identifiable information will be shared.
• Taking part in this study is voluntary.You are free to decide whether to
participate in this study or to withdraw at any time;your decision will
not result in any loss of benefits to which you are otherwise entitled.
• The results of the special may be intimated to you at the end of the study
period or during the study if anything is found abnormal which may aid
in the management or treatment.
Signature of Investigator Signature of Participant
Date :
  

  

